Compare Apple Inc (AAPL) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs ClearPoint Neuro Inc — how do they compare? Apple Inc trades at $302.24 (market cap $4.45T), while ClearPoint Neuro Inc trades at $15.3 (market cap $454.21M). The key difference: Apple Inc is far larger — about 9797.2× ClearPoint Neuro Inc's market cap, and Apple Inc pays a 0.35% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| AAPL | CLPT | |
|---|---|---|
Market Cap | $4.45T | $454.21M |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $29.60 |
52-Week Low | $224.90 | $8.66 |
Enterprise Value | $4.47T | $488.79M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $304.91, down 1.09% with a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $2.02 vs. $1.89, and 2025 revenue reaching $416.16B. Analyst consensus is bullish with a $337.63 price target, though recent news highlights union tensions and potential Q3 earnings pressure from weaker iPhone sales.
Outlook remains positive given Apple's massive AI user base and consistent earnings beats, but risks include retail challenges, regulatory scrutiny from EU fines, and competitive pressures. The stock offers growth potential with a 27.84% ROE, though current valuation metrics suggest premium pricing.
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
